gonadotropin releasing hormone (GnRH)

Phase 2Small molecule

gonadotropin releasing hormone (GnRH) is one of 101 small molecule programs targeting Hypogonadism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

100

Competitors

Pipeline

Status by Indication[3][1]

Indication

HypogonadismActive, not recruiting

Hypogonadotropic HypogonadismActive, not recruiting

Prostate CancerActive, not recruiting

ObesityActive, not recruiting

HypogonadismPhase 2

Active, not recruiting

Hypogonadotropic HypogonadismPhase 1

Active, not recruiting

Prostate CancerPreclinical

Active, not recruiting

ObesityPreclinical

Active, not recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

gonadotropin releasing hormone (GnRH)

MMassachusetts General Hospital

Phase 2

1 2

Trexall

Alnylam Pharmaceuticals

Preclinical

—3

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 4

Duragesic

CCephalon

Preclinical

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Viagra

VViatris Specialty LLC

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xylocaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypogonadism2 trials

Studying the Effects of 7 Days of Gonadotropin Releasing Hormone (GnRH) Treatment in Men With Hypogonadism

Completed·MMassachusetts General Hospital·Phase 1·NCT00493961·27 enrolled

Follicle Stimulating Hormone (FSH) to Improve Testicular Development in Men With Hypogonadism

Terminated·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 2·NCT00064987·19 enrolled

Prostate Cancer1 trial

Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer

Completed·MMassachusetts General Hospital··NCT00456144·36 enrolled

Adult1 trial

Investigating the Regulation of Reproductive Hormones in Adult Men

Completed·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·N/A·NCT00392457·175 enrolled

Concentration1 trial

Effect of a GnRH Injection on Ghrelin Concentrations in Girls With Suspected Premature Puberty

Completed·RRegion Örebro County·N/A·NCT02431416·13 enrolled

Obesity1 trial

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

Completed·UUniversity of Colorado, Denver·N/A·NCT01381016·30 enrolled

1 more indication

Hypogonadotropic Hypogonadism1 trial

Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)

Completed·MMassachusetts General Hospital·Phase 1·NCT00392756·624 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for gonadotropin releasing hormone (GnRH). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gonadotropin releasing hormone (GnRH) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gonadotropin releasing hormone (GnRH). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Massachusetts General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMassachusetts General Hospital

gonadotropin releasing hormone (GnRH)

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypogonadism2 trials

Prostate Cancer1 trial

Adult1 trial

Concentration1 trial

Obesity1 trial

Hypogonadotropic Hypogonadism1 trial

References

Drug Info

Quick Facts

Related News